title: Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery.
abstract: Sn2 lipase labile phospholipid prodrugs in conjunction with contact-facilitated drug delivery offer an important advancement in Nanomedicine. Many drugs incorporated into nanosystems, targeted or not, are substantially lost during circulation to the target. However, favorably altering the pharmacokinetics and volume of distribution of systemic drug delivery can offer greater efficacy with lower toxicity, leading to new prolonged-release nanoexcipients. However, the concept of achieving Paul Erhlich's inspired vision of a 'magic bullet' to treat disease has been largely unrealized due to unstable nanomedicines, nanosystems achieving low drug delivery to target cells, poor intracellular bioavailability of endocytosed nanoparticle payloads, and the substantial biological barriers of extravascular particle penetration into pathological sites. As shown here, Sn2 phospholipid prodrugs in conjunction with contact-facilitated drug delivery prevent premature drug diffusional loss during circulation and increase target cell bioavailability. The Sn2 phospholipid prodrug approach applies equally well for vascular constrained lipid-encapsulated particles and micelles the size of proteins that penetrate through naturally fenestrated endothelium in the bone marrow or thin-walled venules of an inflamed microcirculation. At one time Nanomedicine was considered a 'Grail Quest' by its loyal opposition and even many in the field adsorbing the pains of a long-learning curve about human biology and particles. However, Nanomedicine with innovations like Sn2 phospholipid prodrugs has finally made 'made the turn' toward meaningful translational success.
authors: Departments of Bioengineering, Materials Science and Engineering, Beckman Institute, University of Illinois, Urbana-Champaign, IL, USA.
authors: Dipanjan
authors: D
authors: Pan
authors: Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.|Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
authors: Christine T N
authors: CT
authors: Pham
authors: Division of Oncology, Department of Medicine, Washington University Medical School, St. Louis, MO, USA.
authors: Katherine N
authors: KN
authors: Weilbaecher
authors: Division of Oncology, Department of Medicine, Washington University Medical School, St. Louis, MO, USA.
authors: Michael H
authors: MH
authors: Tomasson
authors: Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
authors: Samuel A
authors: SA
authors: Wickline
authors: Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
authors: Gregory M
authors: GM
authors: Lanza
mesh_terms: D000818:Animals; D016503:Drug Delivery Systems; D006801:Humans; D008049:Lipase; D008055:Lipids; D008081:Liposomes; D051379:Mice; D053758:Nanoparticles; D011355:Prodrugs
chemical_list: D008055:Lipids; D008081:Liposomes; D011355:Prodrugs; D008049:Lipase